Files
Download Full Text (382 KB)
Description
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) have demonstrated significant clinical benefit in managing diabetes mellitus type 2 (DM2), facilitating chronic weight loss, and potentially improving obstructive sleep apnea. While generally well-tolerated, GLP-1 RAs can be associated with adverse events, including pancreatitis, acute kidney injury (AKI), gastroparesis, nausea, diarrhea, abdominal pain, and decreased appetite. Small bowel obstructions have been found in patients after initiating a GLP-1 RA, with limited case reports on this topic. In this case study, we describe a patient that experienced a small bowel obstruction (SBO) shortly after initiating treatment with Ozempic (a GLP-1 RA).
Publication Date
5-9-2025
Disciplines
Family Medicine
Recommended Citation
Oscar E, Vandenbil M. A case of SBO after initiating Ozempic. Presented at: Research Day Corewell Health West; 2025 May 9; Grand Rapids, MI.
Comments
2025 Research Day Corewell Health West, Grand Rapids, MI, May 9, 2025. Abstract 1768